Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019047921) SHORT PEPTIDE ATR001, MONOCLONAL ANTIBODY PREPARED BY SHORT PEPTIDE AND HAVING FUNCTION OF BIASED REGULATION OF AT1R, AND APPLICATION THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/047921 International Application No.: PCT/CN2018/104608
Publication Date: 14.03.2019 International Filing Date: 07.09.2018
IPC:
C07K 16/28 (2006.01) ,C07K 7/14 (2006.01) ,C12N 5/20 (2006.01) ,A61P 9/10 (2006.01) ,A61P 9/12 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
7
Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04
Linear peptides containing only normal peptide links
14
Angiotensins; Related peptides
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10
Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
12
Fused cells, e.g. hybridomas
16
Animal cells
18
Murine cells, e.g. mouse cells
20
one of the fusion partners being a B lymphocyte
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
10
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
12
Antihypertensives
Applicants:
武汉华纪元生物技术开发有限公司 WUHAN HUAJIYUAN BIOTECHNOLOGIES DEVELOP CO., LTD. [CN/CN]; 中国湖北省武汉市 东湖高新区武汉光谷国际商会大厦A座27层12室 Room No.12, 27th Floor, Block A Wuhan Optics Valley International Commercial Chamber Building, East Lake High-tech Development Zone Wuhan, Hubei 430223, CN
Inventors:
陈霄 CHEN, Xiao; CN
Agent:
武汉开元知识产权代理有限公司 WUHAN KAIYUAN INTELLECTUAL PROPERTY AGENT LTD.; 中国湖北省武汉市 江岸区香港路145号远洋大厦14层 14th Floor, Yuanyang Building No.145, Xianggang Road, Jiang'an District Wuhan, Hubei 430015, CN
Priority Data:
201710807113.608.09.2017CN
Title (EN) SHORT PEPTIDE ATR001, MONOCLONAL ANTIBODY PREPARED BY SHORT PEPTIDE AND HAVING FUNCTION OF BIASED REGULATION OF AT1R, AND APPLICATION THEREOF
(FR) PEPTIDE COURT ATR001, ANTICORPS MONOCLONAL PRÉPARÉ PAR PEPTIDE COURT À FONCTION DE RÉGULATION POLARISÉE DE L'AT1R, ET SON APPLICATION
(ZH) 短肽ATR001以及由短肽制备具有偏向性调节AT1R功能的单克隆抗体和应用
Abstract:
(EN) A short peptide ATR001, a monoclonal antibody that is prepared by a short peptide and that has a function of the biased regulation of AT1R, and an application thereof; the short peptide ATR001 has an amino acid sequence of AFHYESQ, a hybridoma cell CQ8-A2D9, and a storage number thereof is: CCTCC NO: C2017108. Monoclonal antibody technology is used to prepare a monoclonal antibody targeting AT1R, and the antibody may have a function of the biased regulation of AT1R, having a therapeutic effect in vascular remodeling diseases such as hypertension, atherosclerosis and aneurysms.
(FR) La présente invention concerne un peptide court ATR001, un anticorps monoclonal préparé par un peptide court et ayant une fonction de régulation polarisée de l'AT1R, ainsi qu'une application de celui-ci ; le peptide court ATR001 présente une séquence d'acides aminés de AFHYESQ et une cellule d'hybridome CQ8-A2D9, le numéro de dépôt de celui-ci est : CCTCC NO : C20 17108. La présente invention utilise la méthode des hybridomes pour la préparation d'un anticorps monoclonal ciblant AT1R, et l'anticorps peut avoir une fonction de régulation polarisée de l'AT1R, ayant un effet thérapeutique dans des maladies de remodelage vasculaire telles que l'hypertension, l'athérosclérose et les anévrismes.
(ZH) 一种短肽ATR001以及由短肽制备具有偏向性调节AT1R功能的单克隆抗体和应用,该短肽ATR001,其氨基酸序列为AFHYESQ,杂交瘤细胞CQ8-A2D9,其保藏编号为:CCTCC NO:C2017108。运用单克隆抗体技术制备针对AT1R单克隆抗体,且该抗体可以偏向性调节AT1R功能,在血管重构类疾病,如高血压、动脉粥样硬化、动脉瘤中发挥治疗作用。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)